TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 05/01/24

FORT WORTH, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thi...

2024-04-30 04:16:28 ET More on TFF Pharmaceuticals TFF Pharmaceuticals announces $1.2M registered direct offering TFF Pharma gains after portfolio shakeup Seeking Alpha’s Quant Rating on TFF Pharmaceuticals Historical earnings data for TFF Pharmaceutic...

FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented T...

Data Now Available on Company Website Following 8-K Filing Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds of the Oral Tacrolimus Systemic Trough Exposures Gene Expression Biomarke...

New Gene Expression Analysis from Ongoing Phase 2 Study Provides Strong Biomarker Evidence that Treatment with TFF TAC Results in Normalization of Rejection-Related Genes TFF TAC Prevented Rejection at 1/6 of Oral Tacrolimus Dose and with 2/3 of Oral Tacrolimus Systemic Trough Exposures...

2024-04-08 07:39:32 ET More on TFF Pharmaceuticals TFF Pharmaceuticals announces $1.2M registered direct offering TFF Pharma gains after portfolio shakeup Read the full article on Seeking Alpha For further details see: TFF Pharmaceuticals files to sell co...

2024-03-28 17:04:28 ET More on TFF Pharmaceuticals TFF Pharmaceuticals announces $1.2M registered direct offering TFF Pharma gains after portfolio shakeup Read the full article on Seeking Alpha For further details see: TFF Pharmaceuticals GAAP EPS of -$2....

FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology pla...

Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to Demonstrate Antifungal Activity and a Favorable Safety and Tolerability Profile ...

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...